Kwon Bo-Eun, Ahn Jae-Hee, Min Seunghwan, Kim Hyeongseop, Seo Jungheun, Yeo Sang-Gu, Ko Hyun-Jeong
Laboratory of Microbiology and Immunology, Kangwon National University, College of Pharmacy, Chuncheon 24341, Korea.
Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju 28159, Korea.
Immune Netw. 2018 Apr 3;18(2):e17. doi: 10.4110/in.2018.18.e17. eCollection 2018 Apr.
Tuberculosis (TB) is a contagious disease that has been responsible for the death of one billion people in the last 200 years. Until now, the only vaccine approved for the prevention of TB is Bacillus Calmette-Guérin (BCG), which is prepared by attenuating . However, one of the limitations of BCG is that its preventive effect against pulmonary TB varies from person to person. Therefore, there arises a need for a new TB vaccine to replace or supplement BCG. In this review, we have summarized the findings of current clinical trials on preventive and therapeutic TB vaccine candidates. In addition, we have discussed a novel vaccination approach using the cell-based vaccine presenting early secretory antigenic target-6 (ESAT-6), which is a potent immunogenic antigen. The role of ESAT-6 in hosts has also been described.
结核病（TB）是一种传染性疾病，在过去200年里已导致10亿人死亡。到目前为止，唯一被批准用于预防结核病的疫苗是卡介苗（BCG），它是通过减毒制备的。然而，卡介苗的局限性之一是其对肺结核的预防效果因人而异。因此，需要一种新的结核病疫苗来替代或补充卡介苗。在这篇综述中，我们总结了目前关于预防性和治疗性结核病候选疫苗临床试验的结果。此外，我们还讨论了一种使用基于细胞的疫苗呈递早期分泌性抗原靶标6（ESAT-6）的新型疫苗接种方法，ESAT-6是一种强效免疫原性抗原。还描述了ESAT-6在宿主中的作用。
